A pharma intermediate and specialty chemicals company has made a significant capex investment, boosting topline growth and operating margins. With over two decades of experience, the promoter’s family excels in bulk drugs, pharmaceuticals, and fine chemicals. They focus on high-growth industries like Oncology, Electronics, and Health. Investing heavily in research and technologies. With the second generation on board, the story seems to be interesting.